The researchers noted that because cancer cells have this defective cell division, factors like Tudor-SN could give us a way to treat or slow down the growth of cancer. But there's a lot to figure out first. These studies have only been done in a lab on kidney and cervical cancer cells, so the researchers will need to repeat their results again and on other types of cancer cells before they can try them out in humans. For now though, this new study represents both a potentially new way to treat cancer as well as a new way to use gene editing. It will be interesting to see if this treatment could become a stand-alone therapy, or one that gets incorporated into existing treatments.